Robert Prins

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
    Brendan Fong
    Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 7:e32614. 2012
  2. pmc Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway
    Veerauo V Konkankit
    Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
    J Transl Med 9:192. 2011
  3. pmc Cellular and vaccine therapeutic approaches for gliomas
    Michelle J Hickey
    The Joan S, Holmes Memorial Biotherapeutics Research Laboratory, Sanford Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Transl Med 8:100. 2010
  4. pmc Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74 145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
    Cancer Immunol Immunother 57:1279-89. 2008
  5. ncbi request reprint The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
    J Immunol 176:157-64. 2006
  6. ncbi request reprint Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Neurosurgery 58:169-78; discussion 169-78. 2006
  7. ncbi request reprint NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 177:8448-55. 2006
  8. pmc Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    Robert M Prins
    Department of Neurosurgery, Brain Research Institute, the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Clin Cancer Res 17:1603-15. 2011
  9. ncbi request reprint The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine
    Noah Craft
    Division of Dermatology, Department of Medicine and Specialty Training and Advanced Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1747, USA
    J Immunol 175:1983-90. 2005
  10. pmc Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen
    Chengyi J Shu
    Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, CA 90095 1662, USA
    Int Immunol 21:155-65. 2009

Collaborators

Detail Information

Publications30

  1. pmc Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
    Brendan Fong
    Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 7:e32614. 2012
    ....
  2. pmc Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway
    Veerauo V Konkankit
    Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
    J Transl Med 9:192. 2011
    ..However, the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the implementation of targeted immune-based therapies...
  3. pmc Cellular and vaccine therapeutic approaches for gliomas
    Michelle J Hickey
    The Joan S, Holmes Memorial Biotherapeutics Research Laboratory, Sanford Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Transl Med 8:100. 2010
    ..A variety of adoptive immunotherapy trials using ex vivo activated effector cell preparations, cell-based and non-cell-based vaccines, and several combination passive and active immunotherapy approaches are discussed...
  4. pmc Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74 145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
    Cancer Immunol Immunother 57:1279-89. 2008
    ..These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors...
  5. ncbi request reprint The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
    J Immunol 176:157-64. 2006
    ..Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod...
  6. ncbi request reprint Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden
    Robert M Prins
    Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Neurosurgery 58:169-78; discussion 169-78. 2006
    ....
  7. ncbi request reprint NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 177:8448-55. 2006
    ..Our results suggest that a better understanding of the cross-talk between DC and innate immune cells may provide improved methods to vaccinate patients with tumors located both systemically and within the CNS...
  8. pmc Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    Robert M Prins
    Department of Neurosurgery, Brain Research Institute, the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Clin Cancer Res 17:1603-15. 2011
    ..Clinical and immune responses were monitored and correlated with tumor gene expression profiles...
  9. ncbi request reprint The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine
    Noah Craft
    Division of Dermatology, Department of Medicine and Specialty Training and Advanced Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1747, USA
    J Immunol 175:1983-90. 2005
    ..The results of these studies have broad implications for future designs of immunotherapeutic vaccines against tumors and the treatment of metastatic melanoma...
  10. pmc Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen
    Chengyi J Shu
    Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, CA 90095 1662, USA
    Int Immunol 21:155-65. 2009
    ..PET may have significant clinical utility by providing the means to quantify anti-tumor T cells throughout the body and provide early correlates for treatment efficacy...
  11. ncbi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009
    ....
  12. ncbi request reprint Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model
    Robert M Prins
    Department of Surgery Neurosurgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Cancer Res 63:8487-91. 2003
    ..These results suggest that shared MAAs on gliomas can be targeted immunotherapeutically, pointing the way to a new potential treatment option for patients with malignant gliomas...
  13. pmc Bioluminescent imaging of melanoma in live mice
    Noah Craft
    Division of Dermatology, Department of Medicine, Harbor UCLA Medical Center, Los Angeles, California, USA
    J Invest Dermatol 125:159-65. 2005
    ..These models represent an accurate and reproducible means for in vivo melanoma monitoring in preclinical studies...
  14. ncbi request reprint Cellular immunity and immunotherapy of brain tumors
    Robert M Prins
    Division of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6901, USA
    Front Biosci 9:3124-36. 2004
    ..Finally, the current state of immune-based treatment paradigms and future directions will be discussed, paying particular attention to adoptive cellular immunotherapy and tumor vaccine approaches for the treatment of malignant gliomas...
  15. pmc Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824
    Dan D Vo
    Department of Medicine, Division of Hematology Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA
    Cancer Res 69:8693-9. 2009
    ..In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes...
  16. ncbi request reprint Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity
    Robert M Prins
    Maxine Dunitz Neurosurgical Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 172:1602-11. 2004
    ....
  17. ncbi request reprint Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
    Linda M Liau
    Division of Neurosurgery, Department of Surgery, The Brain Research Institute, David Geffen School of Medicine at University of California at Los Angeles, University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 11:5515-25. 2005
    ..As a next step in vaccine development, a phase I clinical trial was established to evaluate this strategy for its feasibility, safety, and induction of systemic and intracranial T-cell responses in patients with glioblastoma multiforme...
  18. ncbi request reprint Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme
    Isaac Yang
    UCLA Division of Neurosurgery, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 6901, USA
    J Neurosurg 100:310-9. 2004
    ..In this article the authors investigated the ability of interferon (IFN)alpha and IFNgamma to upregulate MHC Class I expression and to modulate acid-eluted Class I-bound peptides on human glioblastoma multiforme (GBM) cells in vitro...
  19. ncbi request reprint Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression
    Takahiro Kimura
    Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1390-9. 2007
    ..These studies reveal that APC transduction by LVs could lead to immune reactivity (LV-CMV) or persistence of transgene expression (LV-MHCII), providing a relevant paradigm for vaccination and gene replacement approaches...
  20. pmc Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation
    Jelena Lazovic
    Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Neuro Oncol 14:1465-72. 2012
    ..Our results establish a model system where 2-HG can be monitored noninvasively, which should be helpful in validating 2-HG levels as a prognostic and/or predictive biomarker in glioma...
  21. ncbi request reprint Immunology and immunotherapy in neurosurgical disease
    Robert M Prins
    Division of Neurosurgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Neurosurgery 53:144-52; discussion 152-3. 2003
    ..The objective of this present review is to explore key aspects of recent insights into the cellular interactions involved in neuroimmunology, which may suggest more rational approaches to the immunotherapy of neurosurgical disorders...
  22. ncbi request reprint Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies
    Haumith R Khan-Farooqi
    Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California 90095 6901, USA
    Neurol Res 27:692-702. 2005
    ....
  23. pmc EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
    Deliang Guo
    1Department of Pathology and Laboratory Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Sci Signal 2:ra82. 2009
    ..These results identify a previously undescribed EGFR-mediated prosurvival metabolic pathway and suggest new therapeutic approaches to treating EGFR-activated glioblastomas...
  24. pmc The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
    Deliang Guo
    Department of Pathology and Laboratory Medicine, The David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 106:12932-7. 2009
    ..These results suggest a mechanism by which AICAR inhibits the proliferation of EGFRvIII expressing glioblastomas and point toward a potential therapeutic strategy for targeting EGFR-activated cancers...
  25. ncbi request reprint Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications
    Meng Yin Yang
    Division of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095 6901, USA
    Expert Rev Neurother 6:1481-94. 2006
    ..We will also examine major new immunotherapy approaches that are being actively investigated to treat patients with malignant glioma, and identify some current and future research priorities in this area...
  26. pmc Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate
    Robert M Prins
    N Engl J Med 359:539-41. 2008
  27. ncbi request reprint Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery
    Martin R Graf
    Department of Anatomy and Neurobiology, Medical College of Virginia, Virginia Commonwealth University, P O Box 980709 MCV Station, Richmond, VA 23298 0709, USA
    J Neuroimmunol 140:49-60. 2003
    ..F cells. Intracranial T9.F/IL2/#12 tumors were markedly infiltrated by CD4(+) and CD8(+) T cells, natural killer (NK)-T cells and myeloid progenitor cells, whereas subcutaneous T9.F/IL2/#12 tumors contained an elevated level of NK cells...
  28. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression
    Robert M Prins
    Department of Anatomy, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, MCV Station, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:190-9. 2002
    ..Therefore, we believe that an MSC population is responsible for inhibiting the anti-tumor T cell response, resulting in the enhanced growth of the i.c. glioma, and may represent a significant obstacle to immune-based therapies...
  29. ncbi request reprint Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination
    Martin R Graf
    Department of Anatomy and Division of Neurosurgery, Virginia Commonwealth University Medical College of Virginia, 1101 E Marshall Street, P O Box 980709, Richmond, VA 23198 0709, USA
    Cancer Immunol Immunother 51:179-89. 2002
    ....
  30. ncbi request reprint Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression
    Robert M Prins
    Department of Anatomy and Surgery, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
    J Neurooncol 64:45-54. 2003
    ..Our findings may shed light on the significance of thymic function for anti-glioma immunity and the response to immunotherapeutic treatment paradigms...

Research Grants6

  1. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert M Prins; Fiscal Year: 2010
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  2. Immune targeting of melanoma-associated antigens in glioma
    Robert Prins; Fiscal Year: 2007
    ..World renowned scientists and technology in many disciplines will serve to enhance the ability of Dr. Prins to accomplish the goals set forth in this application. ..
  3. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2007
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  4. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert Prins; Fiscal Year: 2009
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..